

Special Issue

Diagnostic and Therapeutic Approach to Pancreatic Cancer

Message from the Guest Editor

Recently, immunotherapies, such as checkpoint inhibitors (CTLA-4, PDL1) have been investigated (either alone or combined with chemotherapy) for the treatment of PC; however, most have proven to be less effective. Another emerging area for PC treatment includes the targeting of tumor microenvironment. Given that PC consists of dense stroma and the PC microenvironment is highly immunosuppressive, molecules or mechanisms that are involved with PC microenvironment are, thus, under active investigation. Beyond these, DNA damage repair proteins (PARP) inhibitors have also been examined for their potential to treat PC. Another obstacle in the field of PC is the lack of methods for early detection of pancreatic tumors. Recent studies have focused on identifying biomarkers; however, no biomarkers have yet entered clinical trials. The process of understanding the early detection and management of PC is dependent on knowledge of the basic tumor biology as well as determining the disease course (such as risk factors, treatment response, and disease progression) at a population level.

Guest Editor

Dr. Sanchita Rauth

University of Nebraska Medical Center, Omaha, NE, USA

Deadline for manuscript submissions

closed (30 June 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/135384

Biomedicines

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).